Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2012-11-19
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 496
- Registration Number
- NCT01728324
- Locations
- 🇺🇸
1241.36.00005 Boehringer Ingelheim Investigational Site, Bakersfield, California, United States
🇺🇸1241.36.00002 Boehringer Ingelheim Investigational Site, Arlington, Texas, United States
🇦🇺1241.36.61002 Boehringer Ingelheim Investigational Site, Herston, Queensland, Australia
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
- First Posted Date
- 2012-11-14
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 689
- Registration Number
- NCT01726270
- Locations
- 🇺🇸
Boehringer Ingelheim Investigational Site, Richmond, Virginia, United States
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 666
- Registration Number
- NCT01721876
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇫🇷HOP Côte de Nacre, Caen, France
🇫🇷HOP Haut-Lévêque, Pessac, France
Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4340
- Registration Number
- NCT01721837
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 729, Duisburg, Germany
🇩🇪Boehringer Ingelheim Investigational Site 1106, Eckernfoerde, Germany
🇩🇪Boehringer Ingelheim Investigational Site 736, Duisburg, Germany
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2Hyperglycemia
- Interventions
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1413
- Registration Number
- NCT01719003
- Locations
- 🇺🇸
1276.1.10010 Boehringer Ingelheim Investigational Site, Glendale, Arizona, United States
🇺🇸1276.1.10008 Boehringer Ingelheim Investigational Site, Greer, South Carolina, United States
🇬🇹1276.1.50005 Boehringer Ingelheim Investigational Site, Guatemala, Guatemala
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT01711853
- Locations
- 🇳🇱
1160.166.31001 Boehringer Ingelheim Investigational Site, Leiden, Netherlands
Nonivamide/Nicoboxil Ointment in Acute Low Back Pain
- Conditions
- Acute Low Back Pain
- Interventions
- Drug: nonivamide + nicoboxil (Finalgon)Drug: nonivamideDrug: nicoboxilDrug: placebo matching nonivamide + nicoboxil
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 805
- Registration Number
- NCT01708915
- Locations
- 🇩🇪
69.52.49032 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪69.52.49024 Boehringer Ingelheim Investigational Site, Essen, Germany
🇩🇪69.52.49039 Boehringer Ingelheim Investigational Site, Fürth, Germany
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: linagliptin 5mgDrug: linagliptin2.5mg/metformin500mgDrug: linagliptin2.5mg/metformin1000mgDrug: Metformin 1000mgDrug: Metformin 500mg
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 876
- Registration Number
- NCT01708902
- Locations
- 🇨🇳
1288.18.86010 Boehringer Ingelheim Investigational Site, Guangzhou, China
🇨🇳1288.18.86039 Boehringer Ingelheim Investigational Site, Nanchang, China
🇨🇳1288.18.86024 Boehringer Ingelheim Investigational Site, Xi'An, China
Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT01707940
- Locations
- 🇩🇪
1313.7.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3219
- Registration Number
- NCT01707147